Article info
PDFReview
Stargardt macular dystrophy and therapeutic approaches
- Correspondence to Professor Kaoru Fujinami, Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, NHO Tokyo Medical Center, Meguro-ku, Tokyo, Japan; k.fujinami{at}ucl.ac.uk; Michel Michaelides, Institute of Ophthalmology, University College London, London, UK; michel.michaelides{at}ucl.ac.uk
Citation
Stargardt macular dystrophy and therapeutic approaches
Publication history
- Received February 13, 2023
- Accepted October 6, 2023
- First published November 8, 2023.
Online issue publication
March 20, 2024
Article Versions
- Previous version (8 November 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.